Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.

Primary tabs

field_vote: 
No votes yet
Number of included patients: 
Therapeutic intervention: 
Therapeutic Substance(s): 
Disease(s): 
References: 


immunology / launched by the Allergy and Immunology Society of
Thailand." href="AL_get(this,%20'jour',%20'Asian%20Pac%20J%20Allergy%20Immunol.');">Asian Pac J Allergy Immunol.
2006 Mar;24(1):33-45.
Prognostic
improvement of patients with advanced liver cancer after active hexose
correlated compound (AHCC) treatment.

Cowawintaweewat
S
, Manoromana
S
, Sriplung
H
, Khuhaprema
T
, Tongtawe
P
, Tapchaisri
P
, Chaicumpa
W
.
Faculty of Allied Health Sciences, Thammasat
University Rangsit Campus, Patumthani, Thailand.

Most patients with liver cancer are diagnosed
when they are not suitable for resection. Although some palliative
approaches can be applied to these patients, the overall survival rate
remains unsatisfactory. Active hexose correlated compound (AHCC), a
newly developed functional food, has been shown to act as a potent
biological response modifier in in vitro experiments. Recently, AHCC was
found to improve the prognosis of hepatocellular carcinoma patients
following surgical treatment. We investigated whether AHCC could prolong
survival and improve the prognosis of patients with advanced liver
cancer. A prospective cohort study was performed with 44 patients with
histologically confirmed liver cancer. All of the patients underwent
supportive care. Survival time, quality of life, clinical and
immunological parameters related to liver function, cellular immunity,
and patient status were determined. Of the 44 patients, 34 and 10
received AHCC and placebo (control) orally, respectively. Patients in
the AHCC treated-group had a significantly prolonged survival when
compared to the control group by Mann-Whitney test (95% CI, p = 0.000).
Quality of life in terms of mental stability, general physical health
status, and ability to have normal activities were significantly
improved after 3 months of AHCC treatment when tested using the Wilcoxon
signed-rank test (on one-sided test, p = 0.028, 0.037, and 0.040,
respectively). The apparent different clinical parameters between the
two groups were the levels of albumin and percentage of lymphocytes with
p-values of 0.000 and 0.026 at 1 and 2 months after treatment,
respectively. Unlike the control patients, AHCC treated-patients with
longer survival time had the tendency of better outcomes since the
levels of AST and ALT had not increased rapidly from their baselines at
follow-up. In addition, the levels of total IL-12 and neopterin were
slightly increased in AHCC treated-patients. This study suggests that
AHCC intake could prolong the survival and improve the prognosis of
patients with advanced liver cancer and delay the gradual decline of
their physiological status.